Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Soleno Therapeutics (SLNO) EBITDA Margin (2016 - 2025)

Soleno Therapeutics (SLNO) has disclosed EBITDA Margin for 6 consecutive years, with 47.33% as the latest value for Q4 2025.

  • Quarterly EBITDA Margin changed N/A to 47.33% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 11.08% through Dec 2025, changed N/A year-over-year, with the annual reading at 11.0% for FY2025, 7595826.0% down from the prior year.
  • EBITDA Margin for Q4 2025 was 47.33% at Soleno Therapeutics, up from 39.82% in the prior quarter.
  • The five-year high for EBITDA Margin was 3226.16% in Q1 2025, with the low at 14.85% in Q2 2025.